Heart Transplantation in Mustard Patients Bridged With Continuous Flow Systemic Ventricular Assist Device - A Case Report and Review of Literature.
d-TGA
heart transplantation
mustard procedure
pulmonary hypertension
pulmonary hypertension reversal
transposition of the great arteries
ventricular assist device
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
01
2021
accepted:
24
03
2021
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
8
5
2021
Statut:
epublish
Résumé
Thirty four-year-old male with history of D-transposition of the great arteries (D-TGA) who underwent Mustard operation at 14 months of age presented in cardiogenic shock secondary to severe systemic right ventricular failure. Catheterization revealed significantly increased pulmonary pressures. Due to the patient's inotrope dependence and prohibitive pulmonary hypertension, he underwent implantation of a Heart Ware HVAD® for systemic RV support. Within 4 months of continuous flow ventricular assist device (VAD) implantation complete normalization of pulmonary vascular resistance (PVR) was achieved. He ultimately underwent orthotopic heart transplantation with favorable outcomes. This is the second report of complete normalization of PVR following VAD implantation into a systemic RV in <4 months. We conducted a thorough literature review to identify Mustard patients that received systemic RV VAD as a bridge to a successful heart transplantation. In this article, we summarize the outcomes and focus on pulmonary hypertension reversibility following VAD implant.
Identifiants
pubmed: 33959642
doi: 10.3389/fcvm.2021.651496
pmc: PMC8093374
doi:
Types de publication
Case Reports
Langues
eng
Pagination
651496Informations de copyright
Copyright © 2021 Bou Chaaya, Simon, Turrentine, Herrmann, Kay, Guglin, Saleem and Rao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Heart Lung Circ. 2016 May;25(5):e69-71
pubmed: 26712611
Ann Thorac Cardiovasc Surg. 2021 Feb 20;27(1):64-67
pubmed: 30101823
J Heart Lung Transplant. 2018 Jan;37(1):89-99
pubmed: 28365175
J Heart Lung Transplant. 2001 Mar;20(3):297-303
pubmed: 11257555
Eur Heart J. 2004 Jul;25(14):1264-70
pubmed: 15246646
Ann Thorac Surg. 2002 Sep;74(3):912-4
pubmed: 12238863
Methodist Debakey Cardiovasc J. 2019 Apr-Jun;15(2):133-137
pubmed: 31384376
Exp Clin Transplant. 2015 Oct;13(5):485-7
pubmed: 25232871
J Heart Lung Transplant. 2015 Sep;34(9):1177-81
pubmed: 26023034
Ann Thorac Surg. 1998 Jun;65(6):1574-8; discussion 1578-9
pubmed: 9647061
Heart. 2010 Jul;96(14):1164
pubmed: 20406764
Artif Organs. 2019 Jan;43(1):90-96
pubmed: 30129258
Ann Thorac Surg. 2007 Jan;83(1):306-8
pubmed: 17184691
Eur J Cardiothorac Surg. 2020 Nov 23;:
pubmed: 33226086